Frank J. Taddeo

Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases

Suzanne M. Garland, Mauricio Hernández‐Ávila, Cosette M. Wheeler et al. · New England Journal of Medicine · 2007 · 1.9K citations

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

Luisa L. Villa, Ronaldo Lúcio Rangel Costa, Carlos Alberto Petta et al. · The Lancet Oncology · 2005 · 1.6K citations

Vaccination, Vaccinology, Vaccine Development +9

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

Luisa L. Villa, Ronaldo Lúcio Rangel Costa, Carlos Alberto Petta et al. · British Journal of Cancer · 2006 · 804 citations · Full text

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

Darron R. Brown, Susanne K. Kjær, Kristján Sigurðsson et al. · The Journal of Infectious Diseases · 2009 · 627 citations · Full text

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

Elmar A. Joura, Sepp Leodolter, Mauricio Hernández‐Ávila et al. · The Lancet · 2007 · 576 citations

Vaccination, L1 Virus-like-particle Vaccine, Vulvar Diseases +12